Biofrontera (NASDAQ: BFRI) announced it will report financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026. Management will host a conference call and webcast at 10:00 a.m. Eastern Time the same day to discuss results and provide a business update. Investors can join via U.S./Canada toll-free 1-877-877-1275, international 1-412-858-5202, or through the webcast link, which will be accessible about 20 minutes before the call.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
BFRI’s prior Q1 earnings release was followed by a 3% move, while this notice only schedules Q2 resu...
Analysis
BFRI’s prior Q1 earnings release was followed by a 3% move, while this notice only schedules Q2 results. The platform record adds a mixed earnings-event history; reported performance and liquidity remain key items to watch.
"with the BF-RhodoLED lamp for photodynamic therapy (PDT)"
Photodynamic therapy is a medical treatment that uses a special light-sensitive substance and a specific type of light to target and destroy abnormal or diseased cells, often in cancer treatment. It is important to investors because advances in this technology can lead to new, minimally invasive treatment options, potentially expanding healthcare markets and driving growth for biotech companies involved in developing such therapies.
actinic keratosismedical
"photodynamic therapy (PDT) of actinic keratosis"
Actinic keratosis is a rough, scaly patch on the skin caused by long-term sun exposure that is considered a precancerous lesion because it can sometimes progress to skin cancer. For investors, its importance lies in the size of the patient pool, clinical trial outcomes, and regulatory approvals for drugs or devices—think of it as a frayed area in fabric that may need repair to prevent a much larger tear, driving demand for treatments and diagnostics.
aminolevulinic acid hydrochloridemedical
"Ameluz® (aminolevulinic acid hydrochloride) Gel"
Aminolevulinic acid hydrochloride is the hydrochloride salt form of aminolevulinic acid, a small-molecule precursor in the body’s heme production pathway that is used as a photosensitizing drug ingredient. When applied or administered, cells convert it into light-sensitive porphyrins that fluoresce or produce reactive oxygen under specific light, enabling detection or targeted destruction of abnormal tissue. It matters to investors because it is an active pharmaceutical ingredient with regulatory, manufacturing, and market implications in diagnostic and photodynamic therapy products.
WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz® (aminolevulinic acid hydrochloride) Gel, 10% with the BF-RhodoLED® lamp for photodynamic therapy (PDT) of actinic keratosis, today announced that it will report financial results for the second quarter ended June 30, 2026 before the market opens on Thursday, August 13, 2026.
Management will host a conference call and webcast the same day at 10:00 a.m. Eastern Time to discuss the results and provide a business update.
Participants dialing in by telephone should ask to be joined into the Biofrontera call. The webcast will be accessible beginning approximately 20 minutes prior to the start of the call.
About Biofrontera Inc.
Biofrontera Inc. (NASDAQ: BFRI) is a U.S. specialty dermatology company focused on the treatment of dermatological conditions. The Company commercializes Ameluz® (aminolevulinic acid hydrochloride) Gel, 10%, together with the BF-RhodoLED® lamp, for photodynamic therapy (PDT) in the treatment of actinic keratosis. Biofrontera Inc. has been a standalone, publicly traded company since its 2021 IPO and operates a wholly owned subsidiary, Biofrontera Discovery GmbH, in Germany. For more information, visit www.biofrontera-us.com.
When will Biofrontera (NASDAQ: BFRI) report its Q2 2026 financial results?
Biofrontera will report its Q2 2026 financial results on Thursday, August 13, 2026, before the market opens. According to Biofrontera, the release will be followed by a conference call and webcast later that morning.
What time is Biofrontera's BFRI Q2 2026 earnings conference call on August 13, 2026?
Biofrontera’s Q2 2026 earnings conference call is scheduled for 10:00 a.m. Eastern Time on August 13, 2026. According to Biofrontera, management will discuss quarterly results and provide a broader business update during the call.
How can investors join the Biofrontera (BFRI) Q2 2026 earnings call by phone?
Investors can join the Biofrontera Q2 2026 call by dialing 1-877-877-1275 in the U.S./Canada or 1-412-858-5202 internationally. According to Biofrontera, participants should ask to be joined into the Biofrontera call when connected.
How do I access the Biofrontera (BFRI) Q2 2026 earnings webcast?
The Biofrontera Q2 2026 earnings webcast is available at https://event.choruscall.com/mediaframe/webcast.html?webcastid=a2Bp6alz. According to Biofrontera, the webcast will be accessible approximately 20 minutes before the 10:00 a.m. Eastern Time start.
What will be discussed on Biofrontera's Q2 2026 earnings call for BFRI shareholders?
The Q2 2026 earnings call will cover Biofrontera’s financial results and a general business update. According to Biofrontera, company management will host the call and discuss performance for the quarter ended June 30, 2026.
Where is Biofrontera, ticker BFRI, headquartered and what is its business focus?
Biofrontera is headquartered in Woburn, Massachusetts, and focuses on U.S. specialty dermatology. According to Biofrontera, it commercializes Ameluz Gel, 10% with the BF-RhodoLED lamp for photodynamic therapy of actinic keratosis.
